Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Acer Therapeutics Inc (ACER)

Acer Therapeutics Inc (ACER)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 34,601
  • Shares Outstanding, K 15,310
  • Annual Sales, $ 1,260 K
  • Annual Income, $ -15,370 K
  • 60-Month Beta 1.28
  • Price/Sales 26.61
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade ACER with:

Options Overview Details

View History
  • Implied Volatility 173.31% ( +17.18%)
  • Historical Volatility 67.12%
  • IV Percentile 96%
  • IV Rank 39.97%
  • IV High 359.09% on 09/29/21
  • IV Low 49.60% on 09/28/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 580
  • Volume Avg (30-Day) 102
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 3,431
  • Open Int (30-Day) 3,313

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.34
  • Number of Estimates 2
  • High Estimate -0.15
  • Low Estimate -0.52
  • Prior Year -0.23
  • Growth Rate Est. (year over year) -47.83%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.71 +32.16%
on 05/12/22
2.30 -1.74%
on 05/23/22
+0.07 (+3.20%)
since 04/22/22
3-Month
1.71 +32.16%
on 05/12/22
3.77 -40.05%
on 04/04/22
-0.40 (-15.04%)
since 02/23/22
52-Week
1.68 +34.52%
on 12/06/21
3.77 -40.05%
on 04/04/22
-0.63 (-21.80%)
since 05/21/21

Most Recent Stories

More News
Acer Therapeutics Inc. (ACER) Reports Q1 Loss, Misses Revenue Estimates

Acer Therapeutics Inc. (ACER) delivered earnings and revenue surprises of -172.22% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

ACER : 2.26 (+3.20%)
HEXO : 0.2789 (-0.61%)
Acer Therapeutics Reports Q1 2022 Financial Results and Provides Corporate Update

NEWTON, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development...

ACER : 2.26 (+3.20%)
OptiNose (OPTN) Reports Q1 Loss, Misses Revenue Estimates

OptiNose (OPTN) delivered earnings and revenue surprises of -29.17% and 12.48%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

OPTN : 1.9100 (-1.55%)
ACER : 2.26 (+3.20%)
Acer Therapeutics Announces Agreement with FDA on Special Protocol Assessment for its Phase 3 EDSIVO™ (celiprolol) Trial in Vascular Ehlers-Danlos Syndrome Patients

Phase 3 DiSCOVER clinical trial initiation expected by end of Q2 2022...

ACER : 2.26 (+3.20%)
Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Genetic Metabolic Dieticians International Conference

NEWTON, Mass. and GENEVA, May 06, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER) (“Acer”) and its collaboration partner, Relief...

ACER : 2.26 (+3.20%)
Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Genetic Metabolic Dieticians International Conference

NEWTON, MA and GENEVA, SWITZERLAND / ACCESSWIRE / May 6, 2022 / Acer Therapeutics Inc. (NASDAQ:ACER) ("Acer") and its collaboration partner, Relief Therapeutics Holding SA (SIX:RLF, OTCQB:RLFTF, RLFTY)...

RLFTF : 0.0607 (+2.02%)
RLFTY : 9.2500 (unch)
ACER : 2.26 (+3.20%)
Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Society for Inherited Metabolic Disorders Annual Meeting

NEWTON, MA and GENEVA, SWITZERLAND / ACCESSWIRE / April 12, 2022 / Acer Therapeutics Inc. (NASDAQ:ACER) ("Acer") and its collaboration partner, Relief Therapeutics Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY)...

ACER : 2.26 (+3.20%)
RLFTF : 0.0607 (+2.02%)
RLFTY : 9.2500 (unch)
Acer Therapeutics’ EDSIVO™ (celiprolol) Granted FDA Breakthrough Therapy Designation for Vascular Ehlers-Danlos Syndrome

Discussions ongoing with FDA through special protocol assessment (SPA) seeking agreement on planned pivotal Phase 3 DiSCOVER trial with initiation planned...

ACER : 2.26 (+3.20%)
Acer Therapeutics Regains Compliance with Nasdaq Listing Standard

NEWTON, Mass., March 31, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development...

ACER : 2.26 (+3.20%)
Acer Therapeutics Enrolls First Patient in its Phase 2a Clinical Trial of ACER-801 for Treatment of Moderate to Severe Vasomotor Symptoms Associated with Menopause

Results anticipated in H2 2022...

ACER : 2.26 (+3.20%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Acer Therapeutics Inc. is a pharmaceutical company. It develops therapies for the treatment of ultra-rare diseases with critical unmet medical need. The company's product pipeline consists of Edsivo (TM) and ACER-001 which are in clinical stage. Acer Therapeutics Inc., formerly known as Opexa Therapeutics,...

See More

Key Turning Points

3rd Resistance Point 2.47
2nd Resistance Point 2.39
1st Resistance Point 2.32
Last Price 2.26
1st Support Level 2.17
2nd Support Level 2.09
3rd Support Level 2.02

See More

52-Week High 3.77
Fibonacci 61.8% 2.97
Fibonacci 50% 2.72
Fibonacci 38.2% 2.48
Last Price 2.26
52-Week Low 1.68

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar